GB0139 for Idiopathic Pulmonary Fibrosis

"All available data points to GB0139's safety, thus receiving a score of 2 on our team's rating scale. This drug is currently in Phase 2 clinical trials — there has been some evidence found regarding its security but no efficacy outcomes have yet been established."

"According to clinicaltrials.gov, the recruitment period for this medical trial has now come to a close. The initial post was made on February 19th 2019 and the latest update dates back to May 23rd 2022. Fortunately, 412 other trials are still welcoming participants at present."

"Avanza Medical Research Center in Pensacola, Florida; Broward Research Center in Pembroke Pines, Virginia and TPMG Clinical Research in Williamsburg, Georgia are three of the 24 medical centres currently enrolling for this trial."

"Since its inception in 2019, GB0139 has undergone extensive testing. Initially sponsored by bioRASI LLC, the first trial of 426 participants led to receive Phase 2 drug approval. Currently two active studies are examining GB0139 across 64 cities and 14 countries worldwide."

"Currently, two trials are running for GB0139 with neither of them in the third stage. Most studies related to this medication take place in Marseille, Indiana but there is a total of 126 sites where these experiments are being conducted."

"Unfortunately, this medical trial has stopped recruiting patients. It was first listed on February 19th and most recently updated on May 23rd of 2022. In the mean time, 410 trials are running for usual interstitial pneumonia while 2 studies are enrolling participants for GB0139."